Cargando…

Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients

Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Miceli, Marisa H, Chandrasekar, Pranatharthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269132/
https://www.ncbi.nlm.nih.gov/pubmed/22294858
http://dx.doi.org/10.2147/IDR.S22587
_version_ 1782222451871055872
author Miceli, Marisa H
Chandrasekar, Pranatharthi
author_facet Miceli, Marisa H
Chandrasekar, Pranatharthi
author_sort Miceli, Marisa H
collection PubMed
description Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes.
format Online
Article
Text
id pubmed-3269132
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32691322012-01-31 Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients Miceli, Marisa H Chandrasekar, Pranatharthi Infect Drug Resist Review Liposomal amphotericin B is a “true” liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes. Dove Medical Press 2012-01-11 /pmc/articles/PMC3269132/ /pubmed/22294858 http://dx.doi.org/10.2147/IDR.S22587 Text en © 2012 Miceli and Chandrasekar, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Miceli, Marisa H
Chandrasekar, Pranatharthi
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
title Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
title_full Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
title_fullStr Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
title_full_unstemmed Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
title_short Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
title_sort safety and efficacy of liposomal amphotericin b for the empirical therapy of invasive fungal infections in immunocompromised patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269132/
https://www.ncbi.nlm.nih.gov/pubmed/22294858
http://dx.doi.org/10.2147/IDR.S22587
work_keys_str_mv AT micelimarisah safetyandefficacyofliposomalamphotericinbfortheempiricaltherapyofinvasivefungalinfectionsinimmunocompromisedpatients
AT chandrasekarpranatharthi safetyandefficacyofliposomalamphotericinbfortheempiricaltherapyofinvasivefungalinfectionsinimmunocompromisedpatients